To further investigate the mechanisms by which BAP1 regulates pancreatic cancer progression, we analyzed the TCGA-PAAD dataset and found that 28% of the patients in this cohort harbor either homozygous or heterozygous deletions of BAP1, resulting in a significant downregulation of BAP1 mRNA expression (Fig. 2A-B). This evidence concerns the gene BAP1 and pancreatic adenocarcinoma.